DE69824165T2 - Verwendung von chelerythrin und strahlung in der tumortherapie - Google Patents

Verwendung von chelerythrin und strahlung in der tumortherapie Download PDF

Info

Publication number
DE69824165T2
DE69824165T2 DE69824165T DE69824165T DE69824165T2 DE 69824165 T2 DE69824165 T2 DE 69824165T2 DE 69824165 T DE69824165 T DE 69824165T DE 69824165 T DE69824165 T DE 69824165T DE 69824165 T2 DE69824165 T2 DE 69824165T2
Authority
DE
Germany
Prior art keywords
cells
chelerythrine
cell
apoptosis
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69824165T
Other languages
German (de)
English (en)
Other versions
DE69824165D1 (de
Inventor
R. Ralph WEICHSELBAUM
Jose Quintans
J. Steven CHMURA
W. Donald KUFE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Arch Development Corp
Original Assignee
Dana Farber Cancer Institute Inc
Arch Development Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc, Arch Development Corp filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of DE69824165D1 publication Critical patent/DE69824165D1/de
Publication of DE69824165T2 publication Critical patent/DE69824165T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69824165T 1997-03-25 1998-03-25 Verwendung von chelerythrin und strahlung in der tumortherapie Expired - Fee Related DE69824165T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US826814 1997-03-25
US08/826,814 US6025365A (en) 1997-03-25 1997-03-25 Chelerythrine and radiation combined tumor therapy
PCT/US1998/005842 WO1998042339A1 (en) 1997-03-25 1998-03-25 Use of chelerythrine and radiation for tumor therapy

Publications (2)

Publication Number Publication Date
DE69824165D1 DE69824165D1 (de) 2004-07-01
DE69824165T2 true DE69824165T2 (de) 2005-06-09

Family

ID=25247609

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69824165T Expired - Fee Related DE69824165T2 (de) 1997-03-25 1998-03-25 Verwendung von chelerythrin und strahlung in der tumortherapie

Country Status (12)

Country Link
US (1) US6025365A (enExample)
EP (1) EP0971710B1 (enExample)
JP (1) JP2001521552A (enExample)
CN (1) CN1172668C (enExample)
AT (1) ATE267599T1 (enExample)
AU (1) AU737613B2 (enExample)
CA (1) CA2284992A1 (enExample)
DE (1) DE69824165T2 (enExample)
DK (1) DK0971710T3 (enExample)
ES (1) ES2218814T3 (enExample)
PT (1) PT971710E (enExample)
WO (1) WO1998042339A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426351B1 (en) * 2000-08-11 2002-07-30 Dana-Farber Cancer, Inc. Chelerythrine-based therapies for cancer
WO2003005965A2 (en) * 2001-07-11 2003-01-23 Musc Foundation For Research Development Modulators of ceramidase and methods of use based thereon
US20030028097A1 (en) * 2001-08-03 2003-02-06 D'amico Anthony V. Immobilizer probe system and method
WO2004016211A2 (en) * 2002-08-08 2004-02-26 Vanderbilt University Pi3k antagonists as radiosensitizers
JP2004284961A (ja) * 2003-03-19 2004-10-14 Okinawa Pref Gov 抗腫瘍成分をサルカケミカンから抽出した製剤、食品または食品添加物
CN1292750C (zh) * 2003-06-02 2007-01-03 张平 植物来源总生物碱组合物及其药物制剂
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
KR100822887B1 (ko) 2006-10-12 2008-04-17 한국생명공학연구원 치매의 치료 또는 예방을 위한 조성물
ITMI20080284A1 (it) * 2008-02-22 2009-08-23 Indena Spa Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono
CN101904849A (zh) * 2010-08-19 2010-12-08 苏州大学 血根碱制备肿瘤放射治疗增敏药物的应用
CN102552264A (zh) * 2012-02-28 2012-07-11 苏州大学 血根碱在制备电离辐射防护剂中的应用
CN116407537A (zh) * 2023-03-03 2023-07-11 长春中医药大学 一种白屈菜红碱在制备用于治疗卵巢癌的药物中的用途
CN118304300B (zh) * 2024-04-12 2025-03-14 儋州市人民医院 一种具有麻醉作用的组合物及其在制备麻醉药物中的应用
CN119548502A (zh) * 2024-11-19 2025-03-04 中国药科大学 白屈菜红碱在制备黑色素瘤治疗药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US209331A (en) * 1878-10-29 Improvement in medical compounds
US433257A (en) * 1890-07-29 Salve
US2344830A (en) * 1940-08-15 1944-03-21 Wisconsin Alumni Res Found Composition of matter for the chemical fixation of diseased tissue preparatory for surgical removal
US4145412A (en) * 1977-02-14 1979-03-20 Vipont Chemical Company Composition for application to oral cavity and method for preparation thereof
US4406881A (en) * 1980-05-20 1983-09-27 Vipont Laboratories Antimicrobial agent
US4376115A (en) * 1980-08-05 1983-03-08 Mccrorey Howard S Method and composition for treating teeth and method for preparing same
US4599228A (en) * 1981-01-19 1986-07-08 Vipont Laboratories, Inc. Antimicrobial agent
US5324520A (en) * 1988-12-19 1994-06-28 Vipont Pharmaceutical, Inc. Intragingival delivery systems for treatment of periodontal disease
US5137912A (en) * 1991-01-28 1992-08-11 National Science Council Of Republic Of China Chelerythrine inhibits platelet aggregation--a potential anti-aggregation drug
US5571797A (en) * 1994-05-11 1996-11-05 Arch Development Corporation Method of inducing gene expression by ionizing radiation
AU6714396A (en) * 1995-07-28 1997-02-26 Trustees Of Boston University Methods and compositions for treating cell proliferative disorders
HUP9601096A2 (hu) * 1996-04-26 1998-01-28 János Aradi Anti-HIV-aktivitással rendelkező gyógynövényalapú gyógyászati és gyógyhatású készítmény,és vegyületek

Also Published As

Publication number Publication date
CA2284992A1 (en) 1998-10-01
PT971710E (pt) 2004-09-30
CN1172668C (zh) 2004-10-27
CN1255061A (zh) 2000-05-31
ES2218814T3 (es) 2004-11-16
AU737613B2 (en) 2001-08-23
DK0971710T3 (da) 2004-09-27
ATE267599T1 (de) 2004-06-15
US6025365A (en) 2000-02-15
JP2001521552A (ja) 2001-11-06
WO1998042339A1 (en) 1998-10-01
EP0971710A1 (en) 2000-01-19
DE69824165D1 (de) 2004-07-01
AU6869398A (en) 1998-10-20
EP0971710B1 (en) 2004-05-26

Similar Documents

Publication Publication Date Title
DE69824165T2 (de) Verwendung von chelerythrin und strahlung in der tumortherapie
DE60216139T3 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
JP7671327B2 (ja) 消化管間質腫瘍の治療のための併用療法
DE69228928T2 (de) Behandlung von schizophrenie mit hilfe von cholinesteraseinhibitoren
Chmura et al. Decreasing the apoptotic threshold of tumor cells through protein kinase C inhibition and sphingomyelinase activation increases tumor killing by ionizing radiation
DE60216305T2 (de) Zusammensetzungen und Verfahren zur Abgabe von Arzneimittelkombinationen
SK154796A3 (en) Use of rapamycin for the inhibition of neuronal cells necrosis
WO2010014141A1 (en) Methods for regulating cell mitosis by inhibiting serine/threonine phosphatase
CA2459822A1 (en) Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents
WO1997027848A1 (en) SENSITIZATION OF HER2/neu OVER-EXPRESSING CANCER CELLS TO CHEMOTHERAPEUTIC DRUGS
WO1997027848A9 (en) SENSITIZATION OF HER2/neu OVER-EXPRESSING CANCER CELLS TO CHEMOTHERAPEUTIC DRUGS
US6426351B1 (en) Chelerythrine-based therapies for cancer
DE102008010362A1 (de) Sgk1 als therapeutisches und diagnostisches Target für virale Erkrankungen
EP1313476A2 (de) Sgk2 und sgk3 als diagnostische und therapeutische targets
Schenone et al. New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: tyrosine kinase inhibitors and molecules that act by alternative mechanisms
EP0919244A2 (de) Kombinationspräparate für die Therapie von Tumoren
US20040191168A1 (en) Tumor cell killing by cell cycle checkpoint abrogation combined with Inhibition of the classical mitogen activated protein (map) kinase pathway
DE10142996A1 (de) Verwendung von Wirkstoffen mit mu-Opioid-Rezeptor agonistischer Wirkung als Kombinationsarzneimittel zur Krebsbehandlung
Tenzer et al. Signal transduction inhibitors as radiosensitizers
WO2025078276A1 (en) Combination of a parp-1 selective inhibitor and temozolimde and its use in the treatment of glioma
TW202139992A (zh) 用於癌症治療之醫藥組合
AU2007200097A1 (en) Chelerythrine-based therapies for cancer
WO2009103494A2 (de) Sgk1 als therapeutisches und diagnostisches target für karzinomatöse erkrankungen
DE102007008484A1 (de) Pharmazeutische Zubereitung zur Bekämpfung von Metastasen
Carnero et al. Prognostic molecular markers for the cancer therapy with aplidine

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: ARCH DEVELOPMENT CORP., CHICAGO, ILL., US

Owner name: DANA-FARBER CANCER INSTITUTE, INC., BOSTON, MASS.,

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee